Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
EU leaders signed their post-Brexit trade deal with Britain and dispatched it to London on an RAF jet Wednesday(30), setting their seal on a drawn-out divorce just hours before the UK brings its half-century European experiment to an end.
EU chiefs Ursula von der Leyen and Charles Michel, the heads of the European Commission and European Council, smiled at a brief televised ceremony to put their names to the 1,246-page Trade and Cooperation Agreement.
"It has been a long road. It's time now to put Brexit behind us. Our future is made in Europe," von der Leyen said
Britain will leave the European single market and customs union at 11:00pm (2300 GMT) on Thursday(31), the end of a difficult year and of a post-Brexit transition period marked by intense and tortuous trade negotiations.
But first the hefty document, bound in blue leather, will be flown by the Royal Air Force to London for prime minister Boris Johnson to add his signature, as the UK parliament began a rushed debate to clear the decks before the looming deadline.
Introducing the legislation to ratify the deal, Johnson told lawmakers it heralded "a new relationship between Britain and the EU as sovereign equals, joined by friendship, commerce, history, interests and values".
"With this bill we are going to be a friendly neighbour, the best friend and ally the EU could have," he said.
London and Brussels would work "hand in glove whenever our values and interests coincide, while fulfilling the sovereign wish of the British people to live under their own sovereign laws made by their own sovereign parliament", he added.
In Brussels, Michel said: "On major issues, the European Union stands ready to work shoulder to shoulder with the United Kingdom.
"This will be the case on climate change, ahead of the COP 26 in Glasgow, and on the global response to pandemics, in particular with a possible treaty on pandemics."
Johnson's government only published the accompanying UK legislation on Tuesday afternoon -- less than 24 hours before the debate is to start in parliament and an hour after the signing in Brussels.
The government intends to ram all stages of the 85-page European Union (Future Relationship) Bill through the Commons and the House of Lords in one day.
The agreement averted the prospect of a cliff-edge separation which would have seen quotas and tariffs slapped on all cross-Channel trade, exacerbating strains in the middle of the coronavirus pandemic, which has hit Britain harder than most.
'Fishermen unhappy'
British fishermen have accused the government of selling them out.
Services, accounting for 80 per cent of the UK economy, were largely omitted, and the City of London faces an anxious wait to learn on what basis it can continue dealing with Europe in the future.
But a faction of arch-Brexiteers in Johnson's ruling Conservatives gave their blessing to the EU agreement on Tuesday(29), and the main opposition Labour party signalled its reluctant backing, ensuring the legislation will pass.
Despite misgivings among some of his own MPs, who plan to abstain in Wednesday's vote, Labour leader Keir Starmer said neutrality was not an option given the stakes for Britain as it unwinds nearly five decades of integration with the European mainland.
"This is a thin deal, it's got many flaws, but a thin deal is better than no deal," Starmer told MPs.
Indeed, the full consequences of the agreement will only play out in the coming months, and UK businesses will still be grappling with the kind of customs red tape they have avoided for decades in trading across the Channel.
From January 1, there will no longer be free movement of people from Britain to the EU or vice versa.
The UK government is pulling out of a European student exchange programme that has benefited tens of thousands of young people over the years.
Under the deal, musicians are not covered by exemptions allowing for free passage of short-term business visitors in the EU, sparking warnings that continental tours by UK bands will become unviable.
The many British owners of European holiday homes are finding that unless they apply for residency permits, they will face limits on how often they can visit their properties.
Under the compressed legislative calendar, the European Parliament will only debate the Brexit deal after the New Year, but they are expected to eventually nod it through.
Pending that, EU member states gave their green light on Monday(28) for the accord to take provisional effect before Thursday's deadline.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.